Stockholm, November 8, 2021 - Intervacc AB ("Intervacc") announces that the United States Patent and Trademark Office has granted an approval for Intervacc's patent application in the United States for a vaccine against Streptococcus suis infections. The U.S. Patent No. 11,155,585 relates to a vaccine based on recombinant fusion proteins where patent protection is effective until 2037.
The bacterium Streptococcus suis (S. suis) can cause sepsis, arthritis and meningitis in pigs. S. suis infection is one of the most common bacterial causes of fatal infection in recently weaned pigs and is considered a global major health problem in the pig industry. The estimated number of pigs is about 1 billion. S. suis is a zoonotic infection which means that it also affects humans.
"The granted patent is a very important step in developing a vaccine against Streptococcus suis infections which is a serious problem in the pig industry. S. suis infections are treated with antibiotics and a vaccine is also important in the fight against the development of antibiotic-resistant bacteria. Intervacc's technology platform provides vaccines with DIVA capacity, i.e. the ability to distinguish a vaccinated animal from an infected animal. This is especially important when dealing with an endemic zoonotic bacteria that can also affect humans and where the vaccine is used to protect food-producing animals. We use the same technology with recombinant fusion proteins that we used in our vaccine against the horse disease strangles that was recently approved by EMA and we see great opportunities to develop more vaccines based on the same technology." says Andreas Andersson, CEO of Intervacc.
Intervacc's Chief Scientific Officer Dr. Andrew Waller "The technology behind this patent has been developed in collaboration with world-leading researchers at the Karolinska Institutet and the Swedish University of Agricultural Sciences, SLU over a period of many years. We are very pleased to, with the help of this ground-breaking research, obtain a patent that could lead to a vaccine for pigs against this widespread and often deadly infectious disease."
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on November 8, 2021.
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company's research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: firstname.lastname@example.org,Phone: +46 (0)8 - 684 211 10
This information was distributed by Cision http://www.cisionwire.se/